New hope for teens with rare nerve disease: drug trial launches
NCT ID NCT07638566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be followed for safety for another 14 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Ultrasound and blood markers may unlock personalized treatment for rare nerve disease
- Experimental drug aims to tame rare nerve disorder
- Blood filtering vs. antibody therapy: new hope for nerve disorder patients
- New nerve patch could ease pain after biopsy
- New weekly shot could replace IV drips for nerve disease